M&A · Healthcare · Pharmaceutical Preparations
Webster Equity Partners to acquire Lifecore Biomedical, Inc.
Announced Sep 28, 2026 · Pending Oct 30, 2026
Deal value$238MEV $376M
Premium49.5%To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash$6.28 per share
Transaction
- Acquirer
- Webster Equity Partners
- Target
- Lifecore Biomedical, Inc. (LFCR)
- Buyer type
- Private equity
- Offer price per share
- $6.28
- Enterprise value
- $376M
- Status
- Pending Oct 30, 2026
Deal protections
- Break fee (target pays)
- $10.0M · 4.2%
- Reverse fee (buyer pays)
- $16.2M · 6.8%
- Go-shop
- Go-shop
- Financing
- Committed · Morgan Stanley, BMO Capital Markets
Advisors
- To the acquirer
- Morgan Stanley
- To the target
- Craig-Hallum
Sector context · Healthcare
- Comparable deals
- 105 in the prior 24 months
- Premium
- 49.5% vs. 43.0% sector median
- EV / Adj. EBITDA
- Sector median 10.7x
- Break fee
- 4.2% vs. 3.5% sector median
Timeline
- AnnouncedSep 28, 2026
- Proxy filedOct 30, 2026
- Definitive proxyPending
- Shareholder votePending
- ClosedPending